Considering that PRMT6 promotes glioblastoma progression and Wnt-β-catenin pathway activation through YTHDF2, and that inhibiting its enzymatic activity reduces YTHDF2 expression, we explored whether this inhibition could suppress malignant phenotypes in glioblastoma. Here, PRMT6 is linked to glioblastoma.